Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Down 0% – Here’s Why

Shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) dropped 0% during trading on Monday . The stock traded as low as $10.74 and last traded at $10.7450. Approximately 25,141 shares were traded during trading, an increase of 242% from the average daily volume of 7,348 shares. The stock had previously closed at $10.75.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Drugs Made In America Acquisition in a report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Drugs Made In America Acquisition Stock Down 0.0%

The business has a fifty day moving average price of $10.68 and a 200 day moving average price of $10.58.

Institutional Investors Weigh In On Drugs Made In America Acquisition

Several institutional investors have recently bought and sold shares of the company. Sandia Investment Management LP bought a new position in shares of Drugs Made In America Acquisition during the 3rd quarter worth approximately $161,000. Quarry LP acquired a new position in Drugs Made In America Acquisition during the third quarter worth $161,000. Lineage Point Capital LP bought a new position in Drugs Made In America Acquisition in the fourth quarter valued at $330,000. Shaolin Capital Management LLC bought a new position in Drugs Made In America Acquisition in the second quarter valued at $1,020,000. Finally, JPMorgan Chase & Co. acquired a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at $1,024,000.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.